EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial.
REDUCE-IT eligibility and preventable first and total cardiovascular events in the US population: an analysis of the National Health and Nutrition Examination Survey (NHANES) [abstract].
Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES.
Response by Bhatt et al to Letter Regarding Article, “REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
Does High-Dose Fish Oil Reduce Cardiovascular Events Via Triglycerides?
Reduction in First and Total Ischemic Events with Icosapent Ethyl Across Baseline Triglyceride Tertiles
REDUCE-IT: Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!